



# Meet AZN Management: **ESMO**

Investor Event – Faculty Biographies

20 October 2025



# Pascal Soriot

## Chief Executive Officer

---

Pascal is Executive Director and Chief Executive Officer at AstraZeneca. He has been a member of the Board and CEO since October 2012. Pascal has a passion for science and medicine as well as a successful track record of managing change, executing strategy and leading a diverse organisation.

Prior to AstraZeneca, Pascal served as COO of Roche's pharmaceuticals division from 2010 to 2012 and previously as CEO of Genentech where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior roles in numerous major companies around the world. He is a Doctor of Veterinary Medicine and holds an MBA from HEC Paris.

Pascal received a British knighthood for services to life sciences and leadership in the global response to the COVID pandemic in the Queen's Birthday Honours 2022. He is also on the board of the Sustainable Markets Initiative and champions the Health Systems Task Force which aims to accelerate the delivery of net zero, sustainable healthcare.





# Dave Fredrickson

## Executive Vice President, Oncology Haematology Business

---

Dave was appointed Executive Vice-President, Oncology Haematology Business Unit in October 2017 and is responsible for driving growth and maximising the global commercial performance of the AstraZeneca global Oncology portfolio.

Previously, Dave served as President of AstraZeneca Japan and Vice-President, Specialty Care in the US. While in Japan, Dave also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a Director of the Japan Pharmaceutical Manufacturers Association.

Before joining AstraZeneca, Dave worked at Roche/Genentech, where he served in several functions and leadership positions. Prior to this, Dave worked at the Monitor Group, now Monitor Deloitte Group, a global strategy consultancy.

Dave is a graduate of Georgetown University in Washington DC.





# Susan Galbraith

## Executive Vice President, Oncology Haematology R&D

---

Susan was appointed as Executive Vice President, Oncology Haematology Research & Development in July 2021, with responsibility for transforming the productivity and scientific output from Oncology R&D. Over her career, Susan has helped develop 12 approved medicines.

As a clinical oncologist, Susan studied medicine at Manchester and Cambridge Universities and has a PhD from the University of London. In recognition of her contributions to Oncology drug development, she has been awarded an honorary Doctorate of Medical Science from the Institute of Cancer Research, is a Fellow of the Academy of Medical Sciences and elected to the Academy of the American Association for Cancer Research.

Susan is a member of the Cambridge Cancer Centre Executive Committee and the Scientific Advisory Board of the ICR. From 2021 to 2024, she also served on the Board of Directors of the AACR and currently serves on the European Association of Cancer Research Advisory Council.





# Leora Horn

## SVP, Late Development Oncology

---

As Senior Vice President of Late Development Oncology, Leora leads a global team dedicated to advancing innovative and novel therapies through late-stage clinical development and regulatory approval.

Prior to her current role, Leora served as Head of Clinical Development, Late Oncology, leading the development and resourcing for the physicians and scientists responsible advancing studies from early signal seeking to Phase III registrational trials spanning multiple indications. She also served as a Clinical Strategy Head for AstraZeneca's global research and development in lung cancer.

Leora previously worked at Vanderbilt Ingram Cancer Center where she led the lung cancer program and participated as principal investigator on several national and global lung cancer trials and published over 175 papers and book chapters. Leora is an active member, and served on the scientific committees, of the American Society of Clinical Oncology, the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, and the Royal College of Physicians and Surgeons of Canada.





# Sunil Verma

## Senior Vice President, Global Head, Oncology Franchise

---

Sunil Verma is Global Head, Oncology Franchise in AstraZeneca. His leadership is focused on advancing the commercial execution of the Company's transformative medicines in markets across the globe and leading the Oncology business unit strategy to help to lead and build the next wave of portfolio. Dr Verma is internationally recognised for his leadership in helping to transform the cancer paradigms with the development of pivotal medicines across multiple tumor types and settings.

Before joining AstraZeneca in August 2019, Dr Verma was a Medical Oncologist, providing clinical care and expertise with a focus in breast and lung cancer and held several pivotal leadership and research roles in academic medicine over 15 years. He served as Professor and Head of the Department of Oncology at the University of Calgary and the Medical Director of the Tom Baker Cancer Centre from 2015-2019. He also served on faculty at the University of Toronto as Associate Professor and Medical Director of the Breast Cancer Centre at Sunnybrook, Toronto.





# Rebecca Dent

## Head of the Department of Medical Oncology, Chief of the Breast Medical Oncology Service at the National Cancer Center Singapore

---

Dr Rebecca Dent is the Chair of the Division of Medical Oncology and Senior Consultant at the National Cancer Center Singapore.

Dr Dent received her medical degree from McMaster University in Hamilton, Canada, and her graduate degree in clinical epidemiology and biostatistics from the University of Toronto, Canada. She obtained her internal medicine and medical oncology training at the University of Toronto, Canada (Princess Margaret Hospital and the Sunnybrook Odette Cancer Center).

Prior to moving to Singapore in 2011, Dr. Dent was a consultant and Head of Breast Cancer Clinical Trials at the Sunnybrook Odette Cancer Center. Dr Dent's primary research interest is in the field of breast cancer, and she is the principal investigator for multiple local, regional and international clinical trials for the treatment breast cancer. She serves as the chair or co-chair of several scientific committees at ASCO, ESMO, ESMO Asia, ASCO Breakthrough Asia and is the founder and co-chair of the Asia-Pacific Breast Cancer Summit.





# Nadia Harbeck

## Director of the Breast Center, LMU University Hospital

---

Nadia Harbeck, MD, PhD, is Director of the Breast Center, and the Center for Hereditary Breast and Ovarian Cancer and holds the chair for Conservative Oncology at the Dept. of OB&GYN, LMU University Hospital, Munich, Germany.

Prof. Harbeck is currently ESMO Director of Education, and Subject Editor of the ESMO Breast Cancer Guidelines and a member of the ESMO Executive Board. She is member of the ASCO Annual Meeting Educational Committee and a member of the expert panel issuing the German AGO recommendations for breast cancer therapy as well as co-director of the West German Study Group. Prof. Harbeck is principal investigator or steering committee member of numerous breast cancer trials.

Prof. Harbeck is one of the most frequently cited clinical researchers worldwide. She has authored more than 750 papers in peer-reviewed journals and is coordinating editor-in-chief of Breast Care as well as a panel member of several international breast cancer consensus conferences.





# Neal Shore

## Medical Director, START-Carolina Urologic Research Center

---

Neal Shore graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the START-Carolina Urologic Research Center as well as the Global Director, GU Oncology START Cancer Research.

Dr Shore has conducted >500 clinical trials, focusing mainly on genitourinary oncology, and has authored >400 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer Guidelines Committee for Bladder Cancer, as has served on the boards of the Bladder Cancer Advocacy Network, the APCCC Scientific Steering Committee, Maple Tree Cancer Alliance, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy, and the co-chair of the annual AUA International Prostate Cancer Forum. He has served/serves on the editorial boards of Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, JUOP, Everyday Urology Oncology and World Journal of Urology. He is the Editor-in-Chief of Reviews in Urology.

